BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Vertex Pharmaceuticals Sell-Off Presents Buying Opportunity Amid Strong Cystic Fibrosis Franchise
Vertex Pharmaceuticals Sell-Off Presents Buying Opportunity Amid Strong Cystic Fibrosis Franchise
7
2
BTCCSquare news:
Vertex Pharmaceuticals (VRTX) shares dipped following Q2 pipeline setbacks, but the sell-off appears overdone given its robust cystic fibrosis business. The biotech's experimental pain drug VX-993 failed phase 2 testing, while FDA concerns limited suzetrigine's potential label expansion.
Despite these clinical disappointments, Vertex maintains market-leading profitability with its CF therapies generating $2 billion quarterly revenue. The $400 share price now offers an attractive entry point for growth investors, with analysts projecting 15% annual earnings growth through 2025.
By:
